(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

TRANSFORMING THE STANDARD OF CARE

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

TRANSFORMING THE STANDARD OF CARE

ST13

US500000088761250

Class

42

Filing

88761250

Registration

6471854

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

24

Latest update

08/31/2021

Trademark type

Word

Nice classes

42

Filing date

01/16/2020

Registration date

08/31/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

08/31/2021

Last transaction

08/31/2021

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

09/03/2020

First use in commerce

09/03/2020

Drawing code

4

Owner type

99

Owner location

Philadelphia, PA

Examiner

PETTICAN, NATHANIEL

Law office

L80

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

The GOG Foundation, Inc.

Representatives

David J. Marr CLARK HILL PLC

Technical classification

Nice Classes

Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 42

Consulting services in the field of conducting clinical trials and translational researchdevelopment of pharmaceuticalsbiopharmaceuticalsmedical devices; medical and scientific clinical research for others for the production of pharmaceuticalsbiopharmaceuticalsmedical devicesfor the ultimate approval and registration of the foregoing goods; information technology consulting services relating to the collectionreviewanalysis and reporting of clinical trial and drug development information; Software as a service (SAAS) serviceshosting software for use by others for use in connection with the collectionreviewanalysis and reporting of clinical trial and drug development informationproviding temporary use of non-downloadable software for use in connection with the collectionreviewanalysis and reporting of clinical trial and drug development information

Publications

History of USPTO decisions and trademark events.

24 publications found

R.PR

REGISTERED-PRINCIPAL REGISTER

08/31/2021

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

07/27/2021

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

07/26/2021

SUPC

STATEMENT OF USE PROCESSING COMPLETE

07/24/2021

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

07/22/2021

IUAF

USE AMENDMENT FILED

07/12/2021

EISU

TEAS STATEMENT OF USE RECEIVED

07/12/2021

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

01/28/2021

EX1G

SOU EXTENSION 1 GRANTED

01/26/2021

EXT1

SOU EXTENSION 1 FILED

01/26/2021

EEXT

SOU TEAS EXTENSION RECEIVED

01/26/2021

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

07/28/2020

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

06/02/2020

PUBO

PUBLISHED FOR OPPOSITION

06/02/2020

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

05/13/2020

ALIE

ASSIGNED TO LIE

04/27/2020

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

04/17/2020

XAEC

EXAMINER'S AMENDMENT ENTERED

04/06/2020

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

04/06/2020

GNEA

EXAMINERS AMENDMENT E-MAILED

04/06/2020

CNEA

EXAMINERS AMENDMENT -WRITTEN

04/06/2020

DOCK

ASSIGNED TO EXAMINER

04/06/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

01/22/2020

NWAP

NEW APPLICATION ENTERED

01/20/2020

Continuous trademark protection

Get notified about every new filing that threatens TRANSFORMING THE STANDARD OF CARE or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.